TR200402194T2 - Regulation of excitable tissue function via peripherally administered erythropoietin - Google Patents
Regulation of excitable tissue function via peripherally administered erythropoietinInfo
- Publication number
- TR200402194T2 TR200402194T2 TR2004/02194T TR200402194T TR200402194T2 TR 200402194 T2 TR200402194 T2 TR 200402194T2 TR 2004/02194 T TR2004/02194 T TR 2004/02194T TR 200402194 T TR200402194 T TR 200402194T TR 200402194 T2 TR200402194 T2 TR 200402194T2
- Authority
- TR
- Turkey
- Prior art keywords
- erythropoietin
- excitable
- tissues
- tissue function
- excitable tissue
- Prior art date
Links
- 102000003951 Erythropoietin Human genes 0.000 title abstract 3
- 108090000394 Erythropoietin Proteins 0.000 title abstract 3
- 229940105423 erythropoietin Drugs 0.000 title abstract 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title abstract 3
- 210000001519 tissue Anatomy 0.000 abstract 6
- 230000006870 function Effects 0.000 abstract 3
- 108010075944 Erythropoietin Receptors Proteins 0.000 abstract 2
- 102100036509 Erythropoietin receptor Human genes 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000001537 neural effect Effects 0.000 abstract 2
- 208000013016 Hypoglycemia Diseases 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 101710138657 Neurotoxin Proteins 0.000 abstract 1
- 230000004888 barrier function Effects 0.000 abstract 1
- 230000008499 blood brain barrier function Effects 0.000 abstract 1
- 210000001218 blood-brain barrier Anatomy 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000002889 endothelial cell Anatomy 0.000 abstract 1
- 210000005003 heart tissue Anatomy 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 231100000566 intoxication Toxicity 0.000 abstract 1
- 230000035987 intoxication Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000002581 neurotoxin Substances 0.000 abstract 1
- 231100000618 neurotoxin Toxicity 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 210000001525 retina Anatomy 0.000 abstract 1
- 208000023516 stroke disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Addiction (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Memelilerde uyarilabilir doku islevini düzenlemek üzere eritropoietin gibi bir eritropoietin reseptörü etkinligi düzenleyicisinin sistemik olarak uygulanmasi yoluyla uyarilabilir doku islevini korumak veya gelistirmek için yöntemler ve bilesimler temin edilmistir. Uyarilabilir dokular, beyin gibi merkezi nöronal dokular, periferik nöronal dokular, retina ve kalp dokusudur. Uyarilabilir dokularin korunmasi, hipoksiya, felç bozukluklari, nörodejeneratif hastaliklar, hipoglisemi ve nörotoksin zehirlenmelerinin tedavisini temin eder. Islevin gelistirilmesi, ögrenme bellek için kullanislidir. Bulus moleküllerin kan-beyin engeli gibi siki endoteliyal hücre birlesim yerleri engellerinden naklini kolaylastirmak için bilesimler ve yöntemlere de iliskindir; bu nakil molekülün eritropoietin gibi bir eritropoietin reseptörü etkinligi düzenleyicisi ile birlestirilmesi yoluyla gerçeklestirilir.Methods and compositions are provided for maintaining or improving excitable tissue function by systemically administering an erythropoietin receptor activity regulator such as erythropoietin to regulate excitable tissue function in mammals. Excitable tissues are central neuronal tissues such as the brain, peripheral neuronal tissues, retina and heart tissue. The protection of excitable tissues provides treatment for hypoxia, stroke disorders, neurodegenerative diseases, hypoglycemia and neurotoxin intoxications. The function development is useful for learning memory. The invention also relates to compounds and methods for facilitating the transport of molecules of the invention through tight endothelial cell junction barriers such as blood-brain barrier; this transport is carried out by combining the molecule with an erythropoietin receptor activity regulator such as erythropoietin.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29093899A | 1999-04-13 | 1999-04-13 | |
| US54722000A | 2000-04-11 | 2000-04-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR200402194T2 true TR200402194T2 (en) | 2004-10-21 |
Family
ID=26966493
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2001/03785T TR200103785T2 (en) | 1999-04-13 | 2000-04-13 | Regulation of excitable tissue function via erythropoietin administered peripherally |
| TR2004/02194T TR200402194T2 (en) | 1999-04-13 | 2000-04-13 | Regulation of excitable tissue function via peripherally administered erythropoietin |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2001/03785T TR200103785T2 (en) | 1999-04-13 | 2000-04-13 | Regulation of excitable tissue function via erythropoietin administered peripherally |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1171147A4 (en) |
| JP (1) | JP2003520194A (en) |
| KR (2) | KR101012932B1 (en) |
| CN (1) | CN1607957B (en) |
| AU (1) | AU784550B2 (en) |
| BG (1) | BG65353B1 (en) |
| BR (1) | BR0009737A (en) |
| CA (1) | CA2383940A1 (en) |
| CR (1) | CR6501A (en) |
| CZ (1) | CZ20013695A3 (en) |
| EA (1) | EA004766B1 (en) |
| HU (1) | HUP0201598A3 (en) |
| IL (2) | IL145895A0 (en) |
| IS (1) | IS6104A (en) |
| MX (1) | MXPA01010177A (en) |
| NO (1) | NO20014991L (en) |
| NZ (4) | NZ533098A (en) |
| PL (1) | PL352223A1 (en) |
| SK (1) | SK14412001A3 (en) |
| TR (2) | TR200103785T2 (en) |
| WO (1) | WO2000061164A1 (en) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19857609A1 (en) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Use of erythropoietin for the treatment of human cerebral ischemia |
| WO2003089468A1 (en) * | 2002-04-19 | 2003-10-30 | Crucell Holland B.V. | Methods and means for producing proteins with predetermined post-translational modifications |
| US6855544B1 (en) | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
| US8236561B2 (en) | 1999-04-15 | 2012-08-07 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
| US7604960B2 (en) | 1999-04-15 | 2009-10-20 | Crucell Holland B.V. | Transient protein expression methods |
| US7297680B2 (en) | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
| US7192759B1 (en) | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
| US7527961B2 (en) | 1999-11-26 | 2009-05-05 | Crucell Holland B.V. | Production of vaccines |
| US7521220B2 (en) | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
| DE60140054D1 (en) | 2000-06-30 | 2009-11-12 | Tokyo Metropolitan Inst Of Ger | PREVENTIVA AND THERAPEUTICS FOR DEMYELINISATION ASSOCIATED DISEASES |
| DE10043457A1 (en) * | 2000-09-04 | 2002-03-28 | Hannelore Ehrenreich | Processes for treating schizophrenia and related psychoses, and using erythropoietin or erythropoietin derivatives to treat schizophrenia and related psychoses |
| US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| PA8536201A1 (en) * | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | PROTECTION AND IMPROVEMENT OF CELLS, FABRICS AND ORGANS RESPONDING TO Erythropoietin |
| WO2002064085A2 (en) * | 2001-02-02 | 2002-08-22 | Ortho-Mcneil Pharmaceutical, Inc. | Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin |
| US20030118630A1 (en) * | 2001-12-07 | 2003-06-26 | Anthony Cerami | Immune modulation device for use in animals |
| JP4583029B2 (en) | 2001-10-29 | 2010-11-17 | クルセル ホランド ベー ヴェー | Method and method for producing a protein having a predetermined post-translational modification |
| EP1465987B1 (en) | 2001-12-07 | 2008-01-23 | Crucell Holland B.V. | Production of viruses, viral isolates and vaccines |
| ATE359087T1 (en) * | 2002-01-09 | 2007-05-15 | Crucell Holland Bv | USE OF ERYTHROPOIETIN TO TREAT OR PREVENT HEART FAILURE |
| GB0211578D0 (en) * | 2002-05-21 | 2002-06-26 | Univ Belfast | Medicaments |
| US20040122216A1 (en) * | 2002-07-01 | 2004-06-24 | Jacob Nielsen | Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs |
| DE10234192B4 (en) * | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Use of erythropoietin |
| US7396913B2 (en) | 2002-10-14 | 2008-07-08 | Abbott Laboratories | Erythropoietin receptor binding antibodies |
| MXPA05010345A (en) * | 2003-03-27 | 2006-03-08 | Johnson & Johnson | Use of erythropoietin in stroke recovery. |
| US7718363B2 (en) | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
| CN100383238C (en) | 2003-05-09 | 2008-04-23 | 克鲁塞尔荷兰公司 | Cultures of E1-immortalized cells and processes for culturing the same to increase product yields therefrom |
| DE102004004509B4 (en) * | 2004-01-23 | 2010-07-01 | Epoplus Gmbh Co.Kg | Use of low dose erythropoietin to stimulate endothelial progenitor cells as well as organ regeneration and progression slowing of end organ damage |
| AT500929B1 (en) | 2004-11-09 | 2007-03-15 | Medizinische Uni Wien Muw | PHARMACEUTICAL PREPARATION CONTAINING ERYTHROPOIETIN |
| MX364100B (en) | 2005-08-05 | 2019-04-12 | Araim Pharmaceuticals Inc | Tissue protective peptides and uses thereof. |
| US20070072795A1 (en) * | 2005-09-28 | 2007-03-29 | Anton Haselbeck | Treatment of neurodegenerative disorders |
| GB0525540D0 (en) * | 2005-12-15 | 2006-01-25 | Isis Innovation | New treatment |
| DE102006004008A1 (en) | 2006-01-27 | 2007-08-02 | Hannelore Prof. Dr. Dr. Ehrenreich | Treating or preventing multiple sclerosis comprises administering erythropoietin for periods separated by intervals in which no erythropoietin is administered |
| CN101062407A (en) * | 2006-04-29 | 2007-10-31 | 中国科学院上海生命科学研究院 | Function of erythropoietin in the preventing and treating of retinal injury |
| US8133860B2 (en) * | 2006-07-20 | 2012-03-13 | Rosalind Franklin University Of Medicine And Science | Facilitation of resuscitation from cardiac arrest by erythropoietin |
| WO2008086025A2 (en) * | 2007-01-10 | 2008-07-17 | Edison Pharmaceuticals, Inc. | Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity |
| WO2009010107A1 (en) * | 2007-07-19 | 2009-01-22 | Hannelore Ehrenreich | Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis |
| EP2933264A3 (en) | 2008-01-22 | 2015-12-09 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| RU2385746C1 (en) * | 2008-07-18 | 2010-04-10 | Владимир Алексеевич Шатров | Method of treating infantile cerebral paralysis |
| RU2432899C1 (en) * | 2010-03-23 | 2011-11-10 | Владимир Алексеевич Тупиков | Method of predicting recurrence of equinus and equinovarus foot deformations after their early surgery in children with cerebral palsy |
| RU2519695C2 (en) * | 2010-07-21 | 2014-06-20 | Олег Ильич Эпштейн | Medication for treating attention deficit disorder and method of treating attention deficit disorder |
| CN111066727B (en) * | 2019-12-20 | 2021-08-27 | 中国人民解放军陆军军医大学 | Method for constructing mouse model of action mechanism in permeability of hypoxic blood testis barrier |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6197229A (en) * | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | Stable erythropoietin preparation |
| US5614184A (en) * | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
| US5661125A (en) * | 1992-08-06 | 1997-08-26 | Amgen, Inc. | Stable and preserved erythropoietin compositions |
| US20020052309A1 (en) * | 1996-09-11 | 2002-05-02 | Athanasius A. Anagnostou | Method of treating endothelial injury |
| DE19857609A1 (en) * | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Use of erythropoietin for the treatment of human cerebral ischemia |
-
2000
- 2000-04-13 SK SK1441-2001A patent/SK14412001A3/en not_active Application Discontinuation
- 2000-04-13 CA CA002383940A patent/CA2383940A1/en not_active Abandoned
- 2000-04-13 BR BR0009737-3A patent/BR0009737A/en not_active Application Discontinuation
- 2000-04-13 MX MXPA01010177A patent/MXPA01010177A/en active IP Right Grant
- 2000-04-13 NZ NZ533098A patent/NZ533098A/en not_active IP Right Cessation
- 2000-04-13 IL IL14589500A patent/IL145895A0/en unknown
- 2000-04-13 TR TR2001/03785T patent/TR200103785T2/en unknown
- 2000-04-13 EA EA200101073A patent/EA004766B1/en not_active IP Right Cessation
- 2000-04-13 WO PCT/US2000/010019 patent/WO2000061164A1/en active IP Right Grant
- 2000-04-13 EP EP00923344A patent/EP1171147A4/en not_active Ceased
- 2000-04-13 CN CN008087466A patent/CN1607957B/en not_active Expired - Lifetime
- 2000-04-13 PL PL00352223A patent/PL352223A1/en not_active Application Discontinuation
- 2000-04-13 NZ NZ560696A patent/NZ560696A/en not_active IP Right Cessation
- 2000-04-13 AU AU43487/00A patent/AU784550B2/en not_active Expired
- 2000-04-13 CZ CZ20013695A patent/CZ20013695A3/en unknown
- 2000-04-13 HU HU0201598A patent/HUP0201598A3/en unknown
- 2000-04-13 NZ NZ545478A patent/NZ545478A/en not_active IP Right Cessation
- 2000-04-13 JP JP2000610496A patent/JP2003520194A/en active Pending
- 2000-04-13 KR KR1020077021154A patent/KR101012932B1/en not_active Expired - Fee Related
- 2000-04-13 TR TR2004/02194T patent/TR200402194T2/en unknown
- 2000-04-13 NZ NZ514690A patent/NZ514690A/en not_active IP Right Cessation
- 2000-04-13 KR KR1020017013093A patent/KR100883232B1/en not_active Expired - Fee Related
-
2001
- 2001-10-11 IS IS6104A patent/IS6104A/en unknown
- 2001-10-11 IL IL145895A patent/IL145895A/en not_active IP Right Cessation
- 2001-10-12 NO NO20014991A patent/NO20014991L/en not_active Application Discontinuation
- 2001-10-26 BG BG106058A patent/BG65353B1/en unknown
- 2001-11-13 CR CR6501A patent/CR6501A/en not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR200402194T2 (en) | Regulation of excitable tissue function via peripherally administered erythropoietin | |
| Man et al. | Role of nitric oxide in regulating epidermal permeability barrier function | |
| BR9714677A (en) | "3-pyridyl enantiomers and their use as analgesics" | |
| US10568819B2 (en) | Skin enhancing compositions and methods | |
| DE60228857D1 (en) | AMINO PHTALAZINONE DERIVATIVES, USE AS KINASE INHIBITORS, PREPARATION AND PHARMACEUTICAL COMPOSITION | |
| PT740650E (en) | CO-DRUGS AS A METHOD OF CONTROLLED DRUG ADMINISTRATION | |
| ATE555789T1 (en) | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | |
| DE69535805D1 (en) | New carbamate and urea derivatives as anti-multidrug resistance agents | |
| TR200103469T2 (en) | Prevention and treatment of amyloidogenic disease | |
| BR9811818A (en) | Use of a compound, compound, and pharmaceutical composition | |
| DE69130859D1 (en) | THERAPEUTIC USES OF MELANINE | |
| WO2016002767A1 (en) | Composition for external application | |
| ATE280758T1 (en) | AGENTS FOR PROTECTING NERVE CELLS | |
| BRPI0417820A (en) | azabicyclic heterocycles as cannabinoid receptor modulators | |
| Gatson et al. | High therapeutic potential of positive allosteric modulation of α7 nAChRs in a rat model of traumatic brain injury: proof-of-concept | |
| ECSP055719A (en) | TIAZOL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | |
| US10682333B2 (en) | Composition for inhibiting formation of SNARE complex, containing myricetin derivatives | |
| ATE308545T1 (en) | CHLOROPHYLL AND BACTERIOCHLOROPHYL ESTERS, THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| AR029025A1 (en) | DERIVATIVES OF ADENOSINA N6 HETEROCICLIC 5 'MODIFIED, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF A MEDICINAL PRODUCT | |
| JP2003137783A (en) | Composition and method for using pyridinium derivative for cosmetic and therapeutic application | |
| Powers et al. | Laser photochemotherapy of rhodamine-123 sensitized human glioma cells in vitro | |
| JP2004323525A (en) | Novel heterocyclic derivative of 2-oxothiazolidine-4-carboxylic acid and use as an effective photoprotective agent | |
| Namjoshi et al. | Cyclic peptides as potential therapeutic agents for skin disorders | |
| EP1060734B1 (en) | Use of cyclic enamines as sun protection agents | |
| KR101453220B1 (en) | Compositions for conditioning |